Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols

Hanna Ksiezak-Reding1, Lap Ho, Ismael Santa-Maria

  • 1Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA. hanna.reding@mssm.edu

Neurobiology of Aging
|January 4, 2011
PubMed

Insights

Grape seed polyphenol extract (GSPE) disrupts the structure of pathological tau filaments in Alzheimer's disease (AD) brains. GSPE treatment alters tau ultrastructure, potentially offering a therapeutic strategy for AD by neutralizing toxic tau aggregates.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Abnormal tau protein folding causes paired helical filaments (PHFs) and neurofibrillary tangles, key markers of Alzheimer's disease (AD).
  • Grape seed polyphenol extract (GSPE) has previously demonstrated efficacy in reducing tau pathology in mouse models.

Purpose of the Study:

  • To investigate the effects of GSPE on the ultrastructure of PHFs isolated from human Alzheimer's disease brains.
  • To elucidate the potential therapeutic mechanisms of GSPE in neutralizing tau pathology.

Main Methods:

  • Transmission electron microscopy (TEM) was used to analyze PHF morphology after GSPE exposure.
  • Immunogold labeling with various anti-tau antibodies assessed changes in protein epitopes.
  • Western blotting confirmed the preservation of tau polypeptides and phospho-epitopes.

Main Results:

  • GSPE induced dose- and time-dependent alterations in PHF morphology, including partial disintegration.
  • Filaments widened and showed signs of unfolding, indicating reduced structural stability.
  • GSPE reduced labeling for mid- and C-terminal tau epitopes while enhancing N-terminal labeling, suggesting specific interactions.

Conclusions:

  • GSPE significantly alters the ultrastructure and conformation of PHFs, leading to their disintegration.
  • The mechanism likely involves noncovalent interactions between polyphenols and proline-rich regions of tau.
  • GSPE shows therapeutic potential for Alzheimer's disease by disrupting toxic tau aggregates.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...